New cancer vaccine developed in Russia shows high effectiveness in early trials

(Web Desk): A newly developed cancer vaccine in Russia has proven to be highly effective in initial trials.

The vaccine, named Entromix, was created by the Russian National Medical Research Radiology Center in collaboration with the Engelhardt Institute of Molecular Biology. It is based on messenger RNA (mRNA) technology, which targets cancer cells within the body.

mRNA technology works by using synthetic copies of messenger RNA molecules to stimulate an immune response. It instructs cells to produce a protein associated with cancer cells, allowing the immune system to identify and attack these harmful cells without damaging healthy ones.

Unlike traditional cancer treatments such as chemotherapy—which harm both cancerous and healthy cells—this vaccine aims to be more targeted and less invasive.

In Entromix, mRNA technology was personalized to address the tumors of individual patients. The initial clinical trial involved 48 patients with colon cancer, and the results were impressive.

All participants developed an immune response, meaning their bodies began to recognize and fight cancer cells. In 68% to 80% of patients, tumors either shrank or stopped growing. Notably, no severe side effects were reported, indicating the vaccine’s safety.

The vaccine was also tested in a limited number of cases involving brain and skin cancers, where results were similarly encouraging.

Following the positive outcomes, the Russian Federal Medical and Biological Agency is now considering fast-tracking the vaccine for potential clinical use.

However, medical experts have urged caution, stating that further research is needed. The Phase I clinical trial primarily focused on the vaccine’s safety and tolerability, not long-term effectiveness. Additionally, the small number of participants (only 48 patients) is not enough to fully confirm its efficacy.

Cancer is a highly complex disease, and success in small-scale trials does not guarantee effectiveness on a larger scale.

Earlier, on December 9, 2024, Alexander Gintsburg, Director of the Gamaleya National Research Center, stated that preclinical trials had shown the vaccine could inhibit tumor growth and prevent metastasis (spread of cancer to other parts of the body).

He also highlighted the use of artificial neural networks in reducing the time needed to develop cancer vaccines. According to him, artificial intelligence (AI) can help create a cancer vaccine in under an hour, by analyzing data from 40,000 to 50,000 tumor sequences to identify and target specific antigens found in cancer cells.

Gintsburg noted that while vaccine development traditionally takes a significant amount of time, their reliance on AI could dramatically accelerate the process—making quick and effective vaccine design a realistic goal.